Ranbaxy Ducks Wider Recall In Glass Particles Class Action

Law360, New York (March 6, 2013, 4:54 PM EST) -- A New Jersey federal judge Tuesday rejected a proposed class action’s demand for a wider recall of Ranbaxy Laboratories Ltd.'s generic version of Lipitor, a setback for patients who claim pills tainted with glass pose a serious health risk.

U.S. District Judge Peter G. Sheridan refused to grant a preliminary injunction that would extend the recall of atorvastatin from the retail level to the consumer level, a move plaintiffs have described as “common sense” despite assurances from the U.S. Food and Drug Administration that grain-of-sand-sized bits...
To view the full article, register now.